Beneficial effect of beraprost sodium plus telmisartan in the prevention of arterial stiffness development in elderly patients with hypertension and cerebral infarction
Abstract Beraprost sodium (BPS, an analogue of prostacyclin) and telmisartan (TS, an angiotensin receptor blocker) have been reported to have a preventive effect on arterial stiffness in patients with cardiovascular diseases. The purpose of this study was to estimate the effects of a combined therap...
Gespeichert in:
Veröffentlicht in: | Prostaglandins, leukotrienes and essential fatty acids leukotrienes and essential fatty acids, 2007-06, Vol.76 (6), p.309-314 |
---|---|
Hauptverfasser: | , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 314 |
---|---|
container_issue | 6 |
container_start_page | 309 |
container_title | Prostaglandins, leukotrienes and essential fatty acids |
container_volume | 76 |
creator | Nakayama, Tomohiro Masubuchi, Yuichi Kawauchi, Kazunori Masaki, Riko Hironaga, Takashi Ishima, Hatsue Torigoe, Mami Shimabukuro, Hiroaki |
description | Abstract Beraprost sodium (BPS, an analogue of prostacyclin) and telmisartan (TS, an angiotensin receptor blocker) have been reported to have a preventive effect on arterial stiffness in patients with cardiovascular diseases. The purpose of this study was to estimate the effects of a combined therapy using BPS and TS on arterial pulse wave velocity (PWV) values in elderly patients with hypertension and cerebral infarction. Over a 3-month period, 80 subjects with hypertension and histories of cerebral infarction received BPS only (120 μg/day p.o.), TS only (40 mg/day p.o.), both BPS and TS, or no medication at all (control). Arterial PWV and ankle brachial indices (ABI) were determined prior to and after 3 months of drug administration. During the follow-up, there were no significant changes in any of the parameters monitored with the exception of a significant decrease in systolic blood pressure in the BPS only, TS only, and BPS plus TS groups when compared to controls. The difference values for PWV in the control group, BPS only group, TS only group, and BPS plus TS group were +232.5, −114.6, −151.5, and −248.1 cm/s, respectively. The reduction values were significantly more pronounced in the BPS plus TS group than in the BPS only ( P =0.037) and the TS only ( P =0.022) groups. When BPS is combined with TS, an overall additive effect is seen in the improvement of PWV in Japanese patients with hypertension and cerebral infarction. This combination therapy is more beneficial than the corresponding monotherapies. |
doi_str_mv | 10.1016/j.plefa.2007.05.004 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_68101230</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S0952327807000695</els_id><sourcerecordid>68101230</sourcerecordid><originalsourceid>FETCH-LOGICAL-c442t-fc26879a83861e091c316b9ce148ce3e7ac185c84e5a1501514b3af88f49878f3</originalsourceid><addsrcrecordid>eNqFkkuLFDEUhQtRnJ7RXyBINrqrMo96pBYK4zA-YMCFug6p1A2dNpUqk9RI_yN_prfshgE3rgLJd06Sc25RvGC0YpS1bw7V4sHqilPaVbSpKK0fFTvWCF5yycXjYkf7hpeCd_KiuEzpQCnljNVPiwvWtaytG74rfr-HANYZpz0Ba8FkMlsyQNRLnFMmaR7dOpHFr4lk8JNLOmYdiAsk74EsEe4hZDeHTYZHEDenlJ21AVIiI577eZkQ2jTgR4j-SBadHW4l8svlPdkfF0BpSJuPDiMxEGGIaOSC1dFs_s-KJ1b7BM_P61Xx_cPtt5tP5d2Xj59vru9KU9c8l9bwVna9lkK2DGjPjGDt0BtgtTQgoNOGycbIGhrNGsoaVg9CWylt3ctOWnFVvD754v9_rpCywj8b8F4HmNekWonhc0ERFCfQYFApglVLdJOOR8Wo2gpSB_W3ILUVpGijsCBUvTzbr8ME44Pm3AgCr86ATkZ7G3UwLj1wsu86yTvk3p44wDDuHUSVDEZqYHQRW1Tj7P7zkHf_6I13weGVP-AI6TCvMWDOiqnEFVVft1naRol2OEZt34g_TWnI5g</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>68101230</pqid></control><display><type>article</type><title>Beneficial effect of beraprost sodium plus telmisartan in the prevention of arterial stiffness development in elderly patients with hypertension and cerebral infarction</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Nakayama, Tomohiro ; Masubuchi, Yuichi ; Kawauchi, Kazunori ; Masaki, Riko ; Hironaga, Takashi ; Ishima, Hatsue ; Torigoe, Mami ; Shimabukuro, Hiroaki</creator><creatorcontrib>Nakayama, Tomohiro ; Masubuchi, Yuichi ; Kawauchi, Kazunori ; Masaki, Riko ; Hironaga, Takashi ; Ishima, Hatsue ; Torigoe, Mami ; Shimabukuro, Hiroaki</creatorcontrib><description>Abstract Beraprost sodium (BPS, an analogue of prostacyclin) and telmisartan (TS, an angiotensin receptor blocker) have been reported to have a preventive effect on arterial stiffness in patients with cardiovascular diseases. The purpose of this study was to estimate the effects of a combined therapy using BPS and TS on arterial pulse wave velocity (PWV) values in elderly patients with hypertension and cerebral infarction. Over a 3-month period, 80 subjects with hypertension and histories of cerebral infarction received BPS only (120 μg/day p.o.), TS only (40 mg/day p.o.), both BPS and TS, or no medication at all (control). Arterial PWV and ankle brachial indices (ABI) were determined prior to and after 3 months of drug administration. During the follow-up, there were no significant changes in any of the parameters monitored with the exception of a significant decrease in systolic blood pressure in the BPS only, TS only, and BPS plus TS groups when compared to controls. The difference values for PWV in the control group, BPS only group, TS only group, and BPS plus TS group were +232.5, −114.6, −151.5, and −248.1 cm/s, respectively. The reduction values were significantly more pronounced in the BPS plus TS group than in the BPS only ( P =0.037) and the TS only ( P =0.022) groups. When BPS is combined with TS, an overall additive effect is seen in the improvement of PWV in Japanese patients with hypertension and cerebral infarction. This combination therapy is more beneficial than the corresponding monotherapies.</description><identifier>ISSN: 0952-3278</identifier><identifier>EISSN: 1532-2823</identifier><identifier>DOI: 10.1016/j.plefa.2007.05.004</identifier><identifier>PMID: 17616452</identifier><language>eng</language><publisher>Kidlington: Elsevier Ltd</publisher><subject>Advanced Basic Science ; Aged ; Aged, 80 and over ; Angiotensin II Type 1 Receptor Blockers - therapeutic use ; Arterial hypertension. Arterial hypotension ; Arteriosclerosis - complications ; Arteriosclerosis - prevention & control ; Benzimidazoles - therapeutic use ; Benzoates - therapeutic use ; Biological and medical sciences ; Blood and lymphatic vessels ; Blood Flow Velocity ; Cardiology. Vascular system ; Cerebral Infarction - complications ; Double-Blind Method ; Drug Therapy, Combination ; Endocrinology & Metabolism ; Epoprostenol - analogs & derivatives ; Epoprostenol - therapeutic use ; Experimental diseases ; Female ; Fundamental and applied biological sciences. Psychology ; Humans ; Hypertension - complications ; Male ; Medical sciences ; Neurology ; Platelet Aggregation Inhibitors - therapeutic use ; Treatment Outcome ; Vascular diseases and vascular malformations of the nervous system ; Vertebrates: endocrinology</subject><ispartof>Prostaglandins, leukotrienes and essential fatty acids, 2007-06, Vol.76 (6), p.309-314</ispartof><rights>2007</rights><rights>2007 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c442t-fc26879a83861e091c316b9ce148ce3e7ac185c84e5a1501514b3af88f49878f3</citedby><cites>FETCH-LOGICAL-c442t-fc26879a83861e091c316b9ce148ce3e7ac185c84e5a1501514b3af88f49878f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0952327807000695$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=18977827$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17616452$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Nakayama, Tomohiro</creatorcontrib><creatorcontrib>Masubuchi, Yuichi</creatorcontrib><creatorcontrib>Kawauchi, Kazunori</creatorcontrib><creatorcontrib>Masaki, Riko</creatorcontrib><creatorcontrib>Hironaga, Takashi</creatorcontrib><creatorcontrib>Ishima, Hatsue</creatorcontrib><creatorcontrib>Torigoe, Mami</creatorcontrib><creatorcontrib>Shimabukuro, Hiroaki</creatorcontrib><title>Beneficial effect of beraprost sodium plus telmisartan in the prevention of arterial stiffness development in elderly patients with hypertension and cerebral infarction</title><title>Prostaglandins, leukotrienes and essential fatty acids</title><addtitle>Prostaglandins Leukot Essent Fatty Acids</addtitle><description>Abstract Beraprost sodium (BPS, an analogue of prostacyclin) and telmisartan (TS, an angiotensin receptor blocker) have been reported to have a preventive effect on arterial stiffness in patients with cardiovascular diseases. The purpose of this study was to estimate the effects of a combined therapy using BPS and TS on arterial pulse wave velocity (PWV) values in elderly patients with hypertension and cerebral infarction. Over a 3-month period, 80 subjects with hypertension and histories of cerebral infarction received BPS only (120 μg/day p.o.), TS only (40 mg/day p.o.), both BPS and TS, or no medication at all (control). Arterial PWV and ankle brachial indices (ABI) were determined prior to and after 3 months of drug administration. During the follow-up, there were no significant changes in any of the parameters monitored with the exception of a significant decrease in systolic blood pressure in the BPS only, TS only, and BPS plus TS groups when compared to controls. The difference values for PWV in the control group, BPS only group, TS only group, and BPS plus TS group were +232.5, −114.6, −151.5, and −248.1 cm/s, respectively. The reduction values were significantly more pronounced in the BPS plus TS group than in the BPS only ( P =0.037) and the TS only ( P =0.022) groups. When BPS is combined with TS, an overall additive effect is seen in the improvement of PWV in Japanese patients with hypertension and cerebral infarction. This combination therapy is more beneficial than the corresponding monotherapies.</description><subject>Advanced Basic Science</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Angiotensin II Type 1 Receptor Blockers - therapeutic use</subject><subject>Arterial hypertension. Arterial hypotension</subject><subject>Arteriosclerosis - complications</subject><subject>Arteriosclerosis - prevention & control</subject><subject>Benzimidazoles - therapeutic use</subject><subject>Benzoates - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Blood and lymphatic vessels</subject><subject>Blood Flow Velocity</subject><subject>Cardiology. Vascular system</subject><subject>Cerebral Infarction - complications</subject><subject>Double-Blind Method</subject><subject>Drug Therapy, Combination</subject><subject>Endocrinology & Metabolism</subject><subject>Epoprostenol - analogs & derivatives</subject><subject>Epoprostenol - therapeutic use</subject><subject>Experimental diseases</subject><subject>Female</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>Humans</subject><subject>Hypertension - complications</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Neurology</subject><subject>Platelet Aggregation Inhibitors - therapeutic use</subject><subject>Treatment Outcome</subject><subject>Vascular diseases and vascular malformations of the nervous system</subject><subject>Vertebrates: endocrinology</subject><issn>0952-3278</issn><issn>1532-2823</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkkuLFDEUhQtRnJ7RXyBINrqrMo96pBYK4zA-YMCFug6p1A2dNpUqk9RI_yN_prfshgE3rgLJd06Sc25RvGC0YpS1bw7V4sHqilPaVbSpKK0fFTvWCF5yycXjYkf7hpeCd_KiuEzpQCnljNVPiwvWtaytG74rfr-HANYZpz0Ba8FkMlsyQNRLnFMmaR7dOpHFr4lk8JNLOmYdiAsk74EsEe4hZDeHTYZHEDenlJ21AVIiI577eZkQ2jTgR4j-SBadHW4l8svlPdkfF0BpSJuPDiMxEGGIaOSC1dFs_s-KJ1b7BM_P61Xx_cPtt5tP5d2Xj59vru9KU9c8l9bwVna9lkK2DGjPjGDt0BtgtTQgoNOGycbIGhrNGsoaVg9CWylt3ctOWnFVvD754v9_rpCywj8b8F4HmNekWonhc0ERFCfQYFApglVLdJOOR8Wo2gpSB_W3ILUVpGijsCBUvTzbr8ME44Pm3AgCr86ATkZ7G3UwLj1wsu86yTvk3p44wDDuHUSVDEZqYHQRW1Tj7P7zkHf_6I13weGVP-AI6TCvMWDOiqnEFVVft1naRol2OEZt34g_TWnI5g</recordid><startdate>20070601</startdate><enddate>20070601</enddate><creator>Nakayama, Tomohiro</creator><creator>Masubuchi, Yuichi</creator><creator>Kawauchi, Kazunori</creator><creator>Masaki, Riko</creator><creator>Hironaga, Takashi</creator><creator>Ishima, Hatsue</creator><creator>Torigoe, Mami</creator><creator>Shimabukuro, Hiroaki</creator><general>Elsevier Ltd</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20070601</creationdate><title>Beneficial effect of beraprost sodium plus telmisartan in the prevention of arterial stiffness development in elderly patients with hypertension and cerebral infarction</title><author>Nakayama, Tomohiro ; Masubuchi, Yuichi ; Kawauchi, Kazunori ; Masaki, Riko ; Hironaga, Takashi ; Ishima, Hatsue ; Torigoe, Mami ; Shimabukuro, Hiroaki</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c442t-fc26879a83861e091c316b9ce148ce3e7ac185c84e5a1501514b3af88f49878f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>Advanced Basic Science</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Angiotensin II Type 1 Receptor Blockers - therapeutic use</topic><topic>Arterial hypertension. Arterial hypotension</topic><topic>Arteriosclerosis - complications</topic><topic>Arteriosclerosis - prevention & control</topic><topic>Benzimidazoles - therapeutic use</topic><topic>Benzoates - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Blood and lymphatic vessels</topic><topic>Blood Flow Velocity</topic><topic>Cardiology. Vascular system</topic><topic>Cerebral Infarction - complications</topic><topic>Double-Blind Method</topic><topic>Drug Therapy, Combination</topic><topic>Endocrinology & Metabolism</topic><topic>Epoprostenol - analogs & derivatives</topic><topic>Epoprostenol - therapeutic use</topic><topic>Experimental diseases</topic><topic>Female</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>Humans</topic><topic>Hypertension - complications</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Neurology</topic><topic>Platelet Aggregation Inhibitors - therapeutic use</topic><topic>Treatment Outcome</topic><topic>Vascular diseases and vascular malformations of the nervous system</topic><topic>Vertebrates: endocrinology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Nakayama, Tomohiro</creatorcontrib><creatorcontrib>Masubuchi, Yuichi</creatorcontrib><creatorcontrib>Kawauchi, Kazunori</creatorcontrib><creatorcontrib>Masaki, Riko</creatorcontrib><creatorcontrib>Hironaga, Takashi</creatorcontrib><creatorcontrib>Ishima, Hatsue</creatorcontrib><creatorcontrib>Torigoe, Mami</creatorcontrib><creatorcontrib>Shimabukuro, Hiroaki</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Prostaglandins, leukotrienes and essential fatty acids</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Nakayama, Tomohiro</au><au>Masubuchi, Yuichi</au><au>Kawauchi, Kazunori</au><au>Masaki, Riko</au><au>Hironaga, Takashi</au><au>Ishima, Hatsue</au><au>Torigoe, Mami</au><au>Shimabukuro, Hiroaki</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Beneficial effect of beraprost sodium plus telmisartan in the prevention of arterial stiffness development in elderly patients with hypertension and cerebral infarction</atitle><jtitle>Prostaglandins, leukotrienes and essential fatty acids</jtitle><addtitle>Prostaglandins Leukot Essent Fatty Acids</addtitle><date>2007-06-01</date><risdate>2007</risdate><volume>76</volume><issue>6</issue><spage>309</spage><epage>314</epage><pages>309-314</pages><issn>0952-3278</issn><eissn>1532-2823</eissn><abstract>Abstract Beraprost sodium (BPS, an analogue of prostacyclin) and telmisartan (TS, an angiotensin receptor blocker) have been reported to have a preventive effect on arterial stiffness in patients with cardiovascular diseases. The purpose of this study was to estimate the effects of a combined therapy using BPS and TS on arterial pulse wave velocity (PWV) values in elderly patients with hypertension and cerebral infarction. Over a 3-month period, 80 subjects with hypertension and histories of cerebral infarction received BPS only (120 μg/day p.o.), TS only (40 mg/day p.o.), both BPS and TS, or no medication at all (control). Arterial PWV and ankle brachial indices (ABI) were determined prior to and after 3 months of drug administration. During the follow-up, there were no significant changes in any of the parameters monitored with the exception of a significant decrease in systolic blood pressure in the BPS only, TS only, and BPS plus TS groups when compared to controls. The difference values for PWV in the control group, BPS only group, TS only group, and BPS plus TS group were +232.5, −114.6, −151.5, and −248.1 cm/s, respectively. The reduction values were significantly more pronounced in the BPS plus TS group than in the BPS only ( P =0.037) and the TS only ( P =0.022) groups. When BPS is combined with TS, an overall additive effect is seen in the improvement of PWV in Japanese patients with hypertension and cerebral infarction. This combination therapy is more beneficial than the corresponding monotherapies.</abstract><cop>Kidlington</cop><pub>Elsevier Ltd</pub><pmid>17616452</pmid><doi>10.1016/j.plefa.2007.05.004</doi><tpages>6</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0952-3278 |
ispartof | Prostaglandins, leukotrienes and essential fatty acids, 2007-06, Vol.76 (6), p.309-314 |
issn | 0952-3278 1532-2823 |
language | eng |
recordid | cdi_proquest_miscellaneous_68101230 |
source | MEDLINE; Elsevier ScienceDirect Journals |
subjects | Advanced Basic Science Aged Aged, 80 and over Angiotensin II Type 1 Receptor Blockers - therapeutic use Arterial hypertension. Arterial hypotension Arteriosclerosis - complications Arteriosclerosis - prevention & control Benzimidazoles - therapeutic use Benzoates - therapeutic use Biological and medical sciences Blood and lymphatic vessels Blood Flow Velocity Cardiology. Vascular system Cerebral Infarction - complications Double-Blind Method Drug Therapy, Combination Endocrinology & Metabolism Epoprostenol - analogs & derivatives Epoprostenol - therapeutic use Experimental diseases Female Fundamental and applied biological sciences. Psychology Humans Hypertension - complications Male Medical sciences Neurology Platelet Aggregation Inhibitors - therapeutic use Treatment Outcome Vascular diseases and vascular malformations of the nervous system Vertebrates: endocrinology |
title | Beneficial effect of beraprost sodium plus telmisartan in the prevention of arterial stiffness development in elderly patients with hypertension and cerebral infarction |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-12T05%3A04%3A14IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Beneficial%20effect%20of%20beraprost%20sodium%20plus%20telmisartan%20in%20the%20prevention%20of%20arterial%20stiffness%20development%20in%20elderly%20patients%20with%20hypertension%20and%20cerebral%20infarction&rft.jtitle=Prostaglandins,%20leukotrienes%20and%20essential%20fatty%20acids&rft.au=Nakayama,%20Tomohiro&rft.date=2007-06-01&rft.volume=76&rft.issue=6&rft.spage=309&rft.epage=314&rft.pages=309-314&rft.issn=0952-3278&rft.eissn=1532-2823&rft_id=info:doi/10.1016/j.plefa.2007.05.004&rft_dat=%3Cproquest_cross%3E68101230%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=68101230&rft_id=info:pmid/17616452&rft_els_id=1_s2_0_S0952327807000695&rfr_iscdi=true |